SK biopharmaceuticals Co., Ltd.

Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.

326030 | KO

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: South Korea
Address:: 경기도 성남시 분당구 판교역로 221, 성남시
Website:: https://www.skbp.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SK Biopharmaceuticals is a global, fully integrated pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies. The company's primary therapeutic area is central nervous system (CNS) disorders, with an expanding pipeline in oncology. Its business model encompasses the entire value chain, from research and development to direct commercialization in key global markets, particularly the United States. The company's flagship product is cenobamate (marketed as XCOPRI® in the U.S.), an anti-seizure medication that has demonstrated significant commercial growth. SK Biopharmaceuticals actively incorporates advanced technologies, including artificial intelligence, to accelerate its drug development process and address unmet medical needs.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for SK biopharmaceuticals Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Date	Filing	Language	Size	Actions
2025-09-16 00:00	Regulatory News Service 투자판단관련주요경영사항	Korean	12.8 KB
2025-08-29 00:00	Regulatory News Service 대규모기업집단현황공시[분기별공시(개별회사용)]	Korean	5.9 KB

Automate Your Workflow. Get a real-time feed of all SK biopharmaceuticals Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SK biopharmaceuticals Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
HIGH TECH PHARM CO.,LTD. Global manufacturer of carbapenem antibiotic APIs for regulated markets.	South Korea	106190
HIKMA Pharmaceuticals PLC Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.	United Kingdom	HIK
HISAMITSU PHARMACEUTICAL CO.,INC. A global leader in transdermal drug delivery systems for OTC and prescription pain relief.	Japan	4530
HLB Genex, Inc. Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.	South Korea	187420
HLB INC. A diversified group in pharma, shipbuilding, life sciences, and professional advisory services.	South Korea	028300
HLB Life Science CO.,LTD. Develops anti-cancer drugs and distributes IVD medical devices and lab supplies internationally.	South Korea	067630
HLB PANAGENE Co., LTD. A global leader in PNA technology for cancer diagnostics and precision medicine.	South Korea	046210
HLB Pep Co., Ltd. Develops and produces GMP peptides, APIs, and custom synthesis for the biopharma industry.	South Korea	196300
HLB PHARMACEUTICAL CO., LTD. Researches cancer drugs and offers pharmaceutical CMO and manufacturing services.	South Korea	047920
HLB SCIENCE Inc. Develops innovative therapeutics and diagnostics for infectious and neurodegenerative diseases.	South Korea	343090